According to a new study published online 28 Feb 2022 (Centio et al., “Inhibition of oxidized nucleotide sanitation by TH1579 and conventional chemotherapy cooperatively enhance oxidative DNA-damage and survival in AML”, Mol Cancer Ther, doi: 10.1158/1535-7163.MCT-21-0185. Online ahead of print),… Continue reading New studies show OXC-101 further improves conventional chemotherapy treatment in Acute Myelom Leukemia (AML)
Press releases
Oxcia reports positive interim data from clinical phase I study in advanced solid cancers
Oxcia reports positive interim data from the first part of the MASTIFF study, a phase 1 dose- escalation study with OXC-101 in patients with advanced solid cancers. Oxcia is a pioneer in oxidative DNA damage and DNA Damage Response (the… Continue reading Oxcia reports positive interim data from clinical phase I study in advanced solid cancers
Oxcia contracts Patheon for manufacturing and further strengthens the organization
Oxcia, a pioneer in oxidative DNA damage and DNA Damage Response (DDR) with a focus on developing new safe treatments for cancer and inflammation, has contracted Patheon for upscaling and production of OXC-101 substance and tablets for the upcoming Phase… Continue reading Oxcia contracts Patheon for manufacturing and further strengthens the organization